Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (IMPALA)

Savara

Status and phase: Completed; Phase 2

Conditions: Autoimmune Pulmonary Alveolar Proteinosis

Treatments: Device: PARI eFlow nebulizer system; Drug: Placebo; Drug: Molgramostim

Study type: Interventional

Funder types: Industry

Identifiers

NCT02702180

MOL-PAP-002

2015-003878-33 (EudraCT Number)

Details and patient eligibility

About

This study evaluates inhaled molgramostim (recombinant human granulocyte macrophage-colony stimulating factor [rhGM-CSF]) in the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) patients. A third of the patients will receive inhaled molgramostim once daily for 24 weeks, a third will receive inhaled molgramostim intermittently (7 days on, 7 days off) for 24 weeks and a third will receive inhaled matching placebo for 24 weeks.

Full description

The trial is a phase 2, randomized, double-blind, placebo-controlled multicentre clinical trial investigating efficacy and safety of inhaled molgramostim (rhGM-CSF) in patients with aPAP.

The trial will include 2 periods; a double-blind treatment period consisting of up to 8 trial visits (Screening, Baseline, and at Weeks 4, 8,12, 16, 20 and 24 after randomisation) and a open-label follow-up period consisting of up to 5 trial visits (at Weeks 4, 12, 24, 36 and 48 post-treatment).

In the double-blind treatment period, eligible subjects will be randomised to treatment for up to 24 weeks with either: 1) inhaled molgramostim (300 µg) once daily (MOL-OD), 2) inhaled molgramostim (300 µg) and matching placebo administered intermittently (7 days on and 7 days off) (MOL-INT) or 3) inhaled placebo once daily (PBO). During the follow-up period, all participants will receive inhaled molgramostim intermittently (7 days on, 7 days off). During the trial, whole lung lavage (WLL) may be applied as rescue therapy in case of significant clinical worsening.

Enrollment: 139 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aPAP diagnosed by computed tomography, or by biopsy, or by Broncho Alveolar Lavage (BAL), and by increased GM-CSF autoantibodies in serum.
• Stable or progressive aPAP during a minimum period of 2 months prior to the Baseline visit.
• Arterial oxygen tension (PaO2) <75 mmHg/<10 kilo Pascal (kPa) at rest, OR desaturation of >4 percentage points on the 6MWT
• An alveolar-arterial oxygen difference [(A-a)DO2] of minimum 25 mmHg/3.33 kPa
• Female or male ≥18 years of age
• Females who have been post-menopausal for >1 year or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence), during and until 30 days after last dose of double-blind trial treatment. Females of childbearing potential must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at dosing at Baseline (Visit 2) and must not be lactating
• Males agreeing to use condoms during and until 30 days after last dose of double-blind medication, or males having a female partner who is using adequate contraception as described above
• Willing and able to provide signed informed consent
• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the investigator

Exclusion criteria

• Diagnosis of hereditary or secondary PAP
• WLL within 1 month of Baseline
• Treatment with GM-CSF within 3 months of Baseline
• Treatment with rituximab within 6 months of Baseline
• Treatment with plasmapheresis within 3 months of Baseline
• Treatment with any investigational medicinal product within 4 weeks of Screening
• Concomitant use of sputum modifying drugs such as carbocysteine or ambroxol
• History of allergic reactions to GM-CSF
• Connective tissue disease, inflammatory bowel disease or other autoimmune disorder requiring treatment associated with significant immunosuppression, e.g. more than 10 mg/day systemic prednisolone
• Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product
• History of, or present, myeloproliferative disease or leukaemia
• Known active infection (viral, bacterial, fungal or mycobacterial)
• Apparent pre-existing concurrent pulmonary fibrosis
• Any other serious medical condition which in the opinion of the investigator would make the participant unsuitable for the trial

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

139 participants in 4 patient groups, including a placebo group

Double-blind molgramostim once daily

Experimental group

Description:

Inhalation of molgramostim nebuliser solution 300 mcg once daily for 24 weeks

Treatment:

Drug: Molgramostim

Device: PARI eFlow nebulizer system

Double-blind molgramostim intermittent

Experimental group

Description:

Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 weeks (12 cycles)

Treatment:

Drug: Molgramostim

Device: PARI eFlow nebulizer system

Double-blind placebo

Placebo Comparator group

Description:

Inhalation of placebo nebuliser solution once daily for 24 weeks

Treatment:

Drug: Placebo

Device: PARI eFlow nebulizer system

Open-label molgramostim intermittent

Experimental group

Description:

Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 or 48 weeks from completion of the double-blind period

Treatment:

Drug: Molgramostim

Device: PARI eFlow nebulizer system